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SUMMARY
To assess possible associations between human leucocyte antigens (HLA) and the achievement of remission during gold 
treatment, HLA typing was performed in 67 rheumatoid arthritis (RA) patients with a gold-induced remission and in 25 control 
RA patients who discontinued gold therapy because oflack of efficacy. Both groups of RA patients showed a significantly higher 
frequency of DR4 antigen and lower frequency of DR6 than a control population. There were no significant differences in HLA 
antigens between remission-responders and non-responders. It is concludcd that HLA typing is not helpful in predicting the 
therapeutic response to parenteral gold therapy.
K ey w o r d s : Human leucocyte antigens, Rheumatoid arthritis, Gold-induced remission.
G o ld  salts have been used in the treatment of patients 
with rheumatoid arthritis (RA) for more than 60 yr [1] 
and are still considered as important disease-modifying 
anti-rheumatic drugs (DMARDs). Controlled studies 
have demonstrated that gold salts suppress the rheum­
atic process in 50-70% of RA patients [2-4] and 
induce remission in approximately 20% of the patients 
[5, 6]. Side-effects to gold requiring drug withdrawal 
occur in about one-third of patients [7]. Therefore the
availability of clinical parameters likely to predict 
successful treatment with gold salts would be of 
interest.
The majority of studies attempting to identify factors 
which predict the response to gold have focused on 
association between human leucocyte antigens (HLA) 
and gold toxicity [8-13]. The most consistent associ­
ation found in these studies was the association be­
tween gold toxicity and HLA-DR3. The results of 
studies that focused on associations HLA
antigens and beneficial therapeutic response to gold 
salts [10, 10-19] are inconsistent.
To investigate associations between HLA antigens 
and therapeutic response to parenteral gold we studied 
HLA phenotypes in a group of RA patients with a 
long-term remission during gold therapy and a control
group of RA patients who had 
because of a lack of efficacy.
gold
PATIENTS A ND  METHODS
Patients
Two groups of parenteral gold-treated with
classical or definite RA according to 1958 American
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Rheumatism Association (ARA) criteria [20] were 
chosen on the basis of their therapeutic response to 
gold (aurothioglucose in oil). The 67 patients with 
a gold-induced remission, designated remission- 
responders, fulfilled the preliminary remission-criteria 
of the ARA [21]. They were all seen by one investig­
ator (SW) in eight rheumatology practices in The 
Netherlands (Leiden, Alkmaar, Haarlem, Dordrecht, 
Rotterdam, Gouda, Enschede and Almelo) between 
1991 and 1993 and were treated with parenteral gold 
for at least 2 yr. None of the patients 
side-effects requiring drug withdrawal.
Since there were not enough patients who stopped 
gold because of a lack of efficacy with detailed pro-
follow-up data in this source
control patients were selected a prospective s
of RA patients as previously reported [22, 23]. This 
study included patients who had met the following 
criteria: classical or definite RA [20], disease duration 
shorter than 1 yr on entry to the study, and not previ­
ously treated with DMARDs. At the time of patient 
selection for the present study 192 patients had been 
included with a mean follow-up duration of 3.9 yr, 
of whom 74 had received parenteral gold. For this 
study all 25 patients were selected who discontinued 
parenteral gold therapy within the first 2 yr of treat­
ment because of a lack of efficacy. These patients were 
designated as ‘non-responders’. Patients who discon­
tinued gold because of both lack of efficacy and gold 
toxicity were excluded from the study.
Since
from
and control patients were derived
two source populations HLA
frequencies of currently gold-treated patients at 
University Hospital Leiden were compared with all 
gold-treated natients included in
-up wh i eh control patients
were selected. This yielded no significant differences 
(data not shown).
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The following data were collected from all patients: 
gender, age at the start of gold therapy, duration 
of gold therapy, serum levels of IgM-rheumatoid 
factor (RF) and HLA-A, B, C and DR typing. HLA 
frequencies of 505 randomly selected healthy Dutch 
blood transfusion donors served as a population 
control group.
HLA typing and statistical analysis
HLA-A, B and C, antigens were determined with a 
standard NIH microlymphocytotoxicity assay and 
HLA-DR antigen typing was done using a two-colour 
fluorescence test using a set of allo-antisera [24].
Significance testing was done using the chi-square 
test with Yates continuity correction, i-test for groups 
or Mann-Whitney test. When necessary, P-values were 
corrected for the Bonferroni inequality by multiplying 
them by the number of HLA-A, B or DR specificities 
tested (Pc). Odds ratios (OR) and their 95% confidence 
intervals (Cl) were calculated for the associations 
between HLA typing and response to gold.
RESULTS
Clinical data of the two groups of RA patients are 
shown in Table I. The male percentage was higher 
among the remission-responders than among the non­
responders, but this difference was not significant. The 
mean age at the start of gold therapy and the percent­
age RF positive patients were approximately the same 
in both groups. The disease duration at the start of gold 
therapy was significantly longer in the remission- 
responders compared to the non-responders, which can 
be ascribed to the policy for earlier treatment with 
DMARDs in the disease course in the source popu­
lation of the control group. The frequency distributions 
of HLA-A, and DR of both groups of RA patients and 
of healthy Dutch blood donors are shown in Table II. 
Comparison of HLA frequencies between the two 
groups of parenteral gold-treated RA patients yielded 
no significant differences after correction for multiple
TABLE I
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Remission No response
(N = 67) (N = 25) P-values*
Male (%) 46 24 0.09
Rheumatoid factor
positive (%) 79 84 0.82
Age at start gold
therapy (yr)f 53.4 (12.2) 56.5 (12.1) 0.27
Time between diagnosis of
RA and start of gold
therapy (yr)$ 3.0 (0 40) 1.0 (0-4) 0.01
Duration of gold
therapy (yr)$ 6.0 (2-27) 0.05 (0.5 2) 0.00
*/ ’-values using chi-square test with Yates correction, /-test or
Mann Whitney test. 
tMean (s .d .) .
^Median (range).
TABLE II
Frequency distributions of HLA antigens in two groups of patients 
with rheumatoid arthritis according to their therapeutic response to 











Al 27 12 32
A2 63 52 48
A3 34 16 33
A9 13 36 19
AIO 9 4 5
A ll 12 4 12
A19 21 44 22
A28 4 8 9
B5 19 12 10
B7 24 16 30
B8 24 24 23
B12 31 12 24
B13 4 8 4
B15 12 36 16
B16 7 8 7
B17 7 12 8
B18 3 4 7
B21 1 0 2
B22 7 0 4
B27 10 12 5
B35 13 16 19
B37 4 0 6
B40 19 24 17
B41 1 0 2
DR1 31 28 21
DR2 25 16 29
DR3 15 20 25
DR4 66* 64* 28
DR5 10 12 18
DR6 12* 12 29
DR7 10 20 22
DR8 3 12 5
DR9 1 0 4
DR10 9 0 5
505)
*JPc-value <0.05 compared with healthy blood
testing. Furthermore, there was no difference in the 
percentage of patients with homozygosity for DR 
antigens between remission-responders and non­
responders.
As expected, the HLA-DR4 frequency was signi­
ficantly increased in both groups of RA 
compared to the healthy blood donors (remission- 
responders vs controls: OR 4.95; 95% Cl 2.88 8.49; 
and non-responders vs controls: OR 4.60; 95% Cl 
1.99-10:6). All other HLA frequencies of both groups 
of RA patients were not significantly different from the 
healthy blood donors after correction of the P -values 
for multiple testing, except for HLA-DR6 which was 
decreased in both groups.
DISCUSSION
The main conclusion of this study is the absence of 
a significant association between HLA antigens and 
therapeutic response to parenteral gold.
Earlier studies reported an increased frequency of 
HLA-DR3 in patients with a beneficial therapeutic
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response to gold [10, 14, 15], However, gold-induced 
proteinuria [9-11, 13, 25-28], thrombocytopenia [8, 25] 
and dermatitis [10, 13, 27, 29] have also been reported 
to be associated with HLA-DR3. Moreover, side- 
effects were reported to occur more frequently in 
responders compared with non-responders in several 
studies on gold-treated RA patients [10, 14,30]. 
Therefore, it is conceivable that the previous reported 
association between HLA-DR3 and beneficial
therapeutic responses to gold could be ascribed to the 
inclusion of patients with gold toxicity. The present 
study included patients with a gold-induced remission 
who were treated with parenteral gold for at least 2 yr 
without developing side-effects requiring drug with­
drawal. This might explain the rather low frequency of 
HLA-DR3 observed in the remission-responders in this 
study. In contrast with previous reports the present 
study included a large sample size of RA patients with 
a gold-induced remission. Therefore, the statistical 
power of this study to find the previously reported 
increased HLA-DR3 frequency in ‘excellent respon­
ders’ [10] compared with non-responders was therefore 
at least 95%.
Although HLA antigens were equally distributed 
between the two groups of RA patients, the distribu­
tion of an other genetic factor, gender, tended to 
be different between remission-responders and non­
responders to gold. The high male percentage observed 
in the remission group is in concordance with other 
studies [5, 14]. However, in the literature there is no 
support for the suggestion of disparity between the 
sexes in response to treatment with gold or other 
DMARDs [16,31,32]. Therefore, instead of a differ­
ence in response to gold the high male percentage 
possibly reflects the conclusions of several studies that 
men with RA fare better than women with RA [33, 34].
In conclusion, no associations were observed 
between HLA antigens and therapeutic response to 
parenteral gold therapy. Therefore, serological HLA 
typing will not be helpful in predicting a gold-induced 
remission. Non-HLA linked genetic variations in meta­
bolic pathways may be more promising in predicting 
responses to drugs [35],
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